Abstract. The 
Calcitonin gene-related peptide (CGRP) is a 37-amino acid polypeptide that results from the tissuespecific processing of the primary RNA transcript of the calcitonin gene (1) .
CGRP is detected in the systemic circulation (2, 3) , and the plasma level of CGRP increases during normal human pregnancy (4) , in endotoxemia (5) or after sensory nerve injury (6) .
CGRP has been reported to have a potent vasodilatory action on various isolated vascular tissue preparations (7) (8) (9) . Intravenous administration of CGRP induced potent dose-related hypotensive and tachycardiac responses in rats and human sub¬ jects (10, 11) .
In addition to its potent vasoactive property, CGRP has an effect on hormonal regulation. CGRP immunoreactivity and specific binding sites for the peptide have been detected in the heart, the adre¬ nal gland, the hypothalamus and the pituitary gland as well as in other organs (12, 13) . CGRP was shown to stimulate renin secretion both in normal human subjects and in rat renal juxtaglomerular cells (14) . More recently CGRP has been found to exhibit stimulatory effects on ANH secretion in vitro in the isolated rat atria (15, 16) . More recently, we reported that CGRP had an inhibitory action on aldosterone secretion in isolated glomerulosa cells (17) . However Measurements of hormones PRA was determined by radioimmunoassay using kits from Dinabott Radioisotope Inst, Tokyo, Japan. The intra-and inter-assay coefficients of variation (CV) were 5.5-6.9 and 3.7-8.2%, respectively (20) . ANH was mea¬ sured by RIA using kits from Eiken Chemical Co, Ltd, Tokyo, Japan (21, 22) . Plasma aldosterone concentration and cortisol were measured by RIA using kits from Daiichi Radioisotope Lab, Ltd, Tokyo, Japan, as previously described (19, 23) . Plasma ACTH and AVP concentrations were measured by RIA using kits from Mitsubishi Yuka Bio-Clinical Lab, Inc, Tokyo, Japan. The intra-and interassay CV of ACTH were 3.8-6.7 and 5.7-7.5% (24) ( Fig. 2) . The increase in cor¬ tisol was not inhibited significantly by the CGRP injection ( Fig. 3) (26) (27) (28) . In the present study these variables, in¬ cluding PRA, ANH and potassium, did not change significantly during angiotensin II infusion with or without CGRP pretreatment. Our latest study has clearly demonstrated that CGRP inhibits aldoste¬ rone secretion in isolated adrenal glomerulosa cells (17) . These results strongly suggest that a small dose of CGRP directly inhibits aldosterone secre¬ tion also in conscious dogs, especially when aldoste¬ rone is stimulated by angiotensin II. These findings agree well with our in vitro study (17 (26) . Recently, Kline et al. (34) reported that CGRP relaxed rat tale artery helical strips in vitro in an intracellular cal¬ cium-dependent manner. Taken together, our findings suggest that CGRP inhibits aldosterone se¬ cretion by reducing the mobilization of calcium in the glomerulosa cells. However, recently Kurtz et al. (35) reported that cytosolic free calcium was not altered by CGRP in the mesangium cells. Further study is needed to clarify the mechanism of this inhibitory action of CGRP.
The present study showed that a small dose of CGRP raised PRA significantly. Kurtz et al. (14) reported that CGRP stimulated renin release in vivo in normal human volunteers and in vitro in isolated rat renal juxtaglomerular cells. The present data are in good accordance with their re¬ sults.
In addition to these hormonal changes, ANH secretion is also stimulated by a small dose of CGRP. Recently, CGRP has been found to stimu¬ late ANH secretion in vitro (15, 16) . In this regard, CGRP may induce ANH secretion without hemodynamic changes.
To summarize our data: an iv bolus of 2 pmol/kg of CGRP inhibited both basal and angiotensin IIstimulated aldosterone secretion significantly and increased PRA, ANH, AVP and ACTH, which might be involved in the regulation of hemodynamics indirectly.
In conclusion, CGRP may participate in the reg¬ ulation of adrenal hormones as well as in the con¬ trol of vascular tones.
